Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen M Fancher

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Cancer Chemotherapy and Pharmacology|September 17, 2020
Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and managementKaren M Fancher, Jeremy J Pappacena
Pharmacotherapy|December 29, 2017
Cabozantinib: A Multitargeted Oral Tyrosine Kinase InhibitorJordan N Markowitz, Karen M Fancher
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 29, 2019
Moxetumomab pasudotox: A first-in-class treatment for hairy cell leukemiaKaren M Fancher, Zachary C Lally-Montgomery
American Journal of Clinical Oncology|December 20, 2013
Off-Target Effects of BCR-ABL and JAK2 InhibitorsMyke R Green, Michael D Newton, Karen M Fancher
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 20, 2015
Comparison of two different formulas for body surface area in adults at extremes of height and weightKaren M Fancher, Alicia J Sacco, Robert C Gwin, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Cancer Chemotherapy and Pharmacology|September 17, 2020
Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and managementKaren M Fancher, Jeremy J Pappacena
Pharmacotherapy|December 29, 2017
Cabozantinib: A Multitargeted Oral Tyrosine Kinase InhibitorJordan N Markowitz, Karen M Fancher
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 29, 2019
Moxetumomab pasudotox: A first-in-class treatment for hairy cell leukemiaKaren M Fancher, Zachary C Lally-Montgomery
American Journal of Clinical Oncology|December 20, 2013
Off-Target Effects of BCR-ABL and JAK2 InhibitorsMyke R Green, Michael D Newton, Karen M Fancher
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 20, 2015
Comparison of two different formulas for body surface area in adults at extremes of height and weightKaren M Fancher, Alicia J Sacco, Robert C Gwin, et al.
Pageof 1